[ES23] イブニングセミナー 23　Brigatinib for ALK-positive non-small cell lung cancer (NSCLC) in the first-line setting: A Korean experience
【同通】

[ES23-1] Brigatinib for ALK-positive non-small cell lung cancer (NSCLC) in the first-line setting: A Korean experience

^○Hye Ryun Kim (Yonsei Cancer Center, Division of Medical Oncology, Yonsei University College of Medicine, Seoul, Korea)